| Titel: | Irritable bowel syndrome: current treatment options |
|---|---|
| Autor: | Ducrotte, P |
| Mediengruppe: | journal article |
| Herausgeber: | --- |
| Zeitschrift: | Presse Medicale |
| Jahr: | 2007 |
| Band: | 36 |
| Heft: | 11 |
| Seiten: | 1619-1626 |
| Sprache: | englisch |
| Abstract: | Relieving abdominal pain is the principal treatment objective for patients with irritable bowel syndrome. No single drug stands out in the treatment strategy for this illness. Antispasmodics, magnesium aluminum silicates, and alverine citrate drugs all remain initial options for treatment although their prescription is impeded by the fact that on increasing number ore no longer approved for reimbursement. Increased dietary fibers often have a harmful effect on symptoms. Some patients are probably intolerant to some foods but there is no satisfactory proof on which to base a restrictive diet. Improved knowledge of the pathophysiology of irritable bowel syndrome has made it possible to diversify treatments that act first on one of the key pathophysiologic elements, visceral hypersensitivity Antidepressants (especially tricyclics) can be used at low doses. Among the serotonergic drugs, serotonin S-HT4 receptors agonists (tegaserod) may be available soon, but the development of 5-HT3 antagonists (alosetron, cilansetron) has been stopped for safety reasons (ischemic colitis and severe constipation). Non-drug options such as hypnosis, psychotherapy relaxation, or yoga, may also be proposed to some patients. Probiotics ore a possible treatment in the future. |